Copyright © 2002 by the European Society of Cardiology.
Dose-dependent effects of folic acid on plasma homocysteine in a randomized trial conducted among 723 individuals with coronary heart disease
revised December 31, 2001; accepted January 2, 2002Abstract
Aims To determine the effects on homocysteine levels of two doses of folic acid compared to placebo, where the high dose is typical of that provided by pharmacological intervention and the low dose approximates that provided by dietary supplementation.
Methods and Results The PACIFIC study was a double-blind, placebo-controlled, factorial randomized trial. Seven hundred and twenty-three individuals with a history of myocardial infarction or unstable angina were recruited from 28 clinical cardiology centres in Australia and New Zealand and randomized to folic acid 2·0mg daily, folic acid 0·2mg daily or placebo. The primary outcome, homocysteine, was measured using a fluorescence polarization immunoassay. Compared to placebo, 2·0mg folic acid reduced homocysteine by 1·8µmol.l–1 [95% confidence interval (CI) 1·3–2·3] and 0·2mg reduced homocysteine by 1·2µmol.l–1 (95% CI 0·8–1·7). The higher dose reduced homocysteine significantly more than the lower dose (P=0·01).
Conclusions Both doses of folic acid reduced homocysteine, but the effects of the 2·0mg dose were about one third greater than the 0·2mg dose. Fortification of foods with folic acid should result in population-wide lower levels of homocysteine but high-dose pharmacological supplementation would produce greater reductions for high-risk individuals. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.
Key Words: Homocysteine, folic acid, coronary heart disease, randomized trial
References
- Graham IM, Daly LE, Refsum HM. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775–1781
[Abstract/Free Full Text] - Perry IJ, Refsum H, Morriw RW. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–1398[CrossRef][Web of Science][Medline]
- Clarke R, Daly L, Robinson K. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991;324:1149–1155[Abstract]
- Boushey CJ, Beresford SAA, Omenn GS. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995;274:1049–1057
[Abstract/Free Full Text] - Arnesen E, Refsum H, Bonaa K. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995;24:704–709
[Abstract/Free Full Text] - Selhub J, Jacques PF, Wilson PW. Vitamin status and intake as primary determinants of homocysteinaemia in an elderly population. JAMA. 1993;270:2693–2698
[Abstract/Free Full Text] - BMJ. 1998;316:894–898
[Abstract/Free Full Text] - Malinow M, Duell P, Hess D. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med. 1998;338:1009–1015
[Abstract/Free Full Text] - Brouwer I, Dusseldorp C, Thomas C. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial. Am J Clin Nutr. 1999;69:99–104
[Abstract/Free Full Text] - Appel L, Miller E, Jee S. Effect of dietary patterns on serum homocysteine: results of a randomised, controlled feeding study. Circulation. 2000;22:852–857
- MacMahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med. 2000;342:50–52[CrossRef][Web of Science][Medline]
- Wilcken D, Wang X, Adachi T. Relationship between homocysteine and superoxide dismutase in homocystinuria: possible relevance to cardiovascular risk. Arterioscler Thromb Vasc Biol. 2000;20:1199–1202
[Abstract/Free Full Text] - Wilcken, D, Wang, X, Sim, S, Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C 677 T mutation, Arterioscler Thromb Vasc Biol . 1996, 16, 878, 82
- Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215
[Free Full Text] - Goyette P, Summer J, Milos R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195–200[CrossRef][Web of Science][Medline]
- Brattstrom, L, Wilcken, D, Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr, 2000, 72, 315, 23
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. S. B Imasa, N. T Gomez, and J. B Nevado Jr Folic Acid-Based Intervention in Non-ST Elevation Acute Coronary Syndromes Asian Cardiovasc Thorac Ann, January 1, 2009; 17(1): 13 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P Quinlivan and J. F Gregory III Reassessing folic acid consumption patterns in the United States (1999 2004): potential effect on neural tube defects and overexposure to folate Am. J. Clinical Nutrition, December 1, 2007; 86(6): 1773 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Homocysteine Lowering Trialists' Collaboration Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials Am. J. Clinical Nutrition, October 1, 2005; 82(4): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Pacific Study Group and B. Neal Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 270 - 276. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||